Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Complement Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive analysis of the ...

Alexion Pharmaceuticals, Inc. ALXN announced a partnership with Complement Pharma to co-develop the preclinical C6 complement inhibitor, CP010, for neurodegenerative disorders. CP010 is a humanized ...

Some of the greatest advancements in modern medicine started with a scientist taking a risk to boldly pursue new areas of research. For scientists at Alexion — a leading biotech company dedicated to ...

Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics Commit Biologics is pioneering a novel approach ...

Complement Pharma is a biotech company focusing on complement inhibition to modify neurodegenerative disease progression. The Company was founded in 2017 by Prof. Frank Baas and Robert Jan Lamers with ...